Octreotide Acetate
Somatostatin analog for acromegaly and neuroendocrine tumors. Potent inhibitor of growth hormone and gastrointestinal peptide secretion, providing sustained hormonal control.
Octreotide Acetate, marketed under the brand name Sandostatin, is a synthetic cyclic octapeptide analogue of somatostatin, a naturally occurring tetradecapeptide hormone. First approved by the FDA in 1988, octreotide acetate was the first somatostatin analogue to enter clinical practice and has since become the gold standard reference for all subsequent somatostatin analogues. Its pharmacologic profile closely mimics that of native somatostatin while offering significantly enhanced potency and duration of action.
| Parameter | Specification |
| CAS | 79517-01-4 |
| Molecular Formula | C₄₉H₆₆N₁₀O₁₀S₂ |
| Molecular Weight | 1019.26 g/mol |
| Category | Oncology/Endocrine |
| Purity | ≥99% |
| Status | GMP-compliant, FDA-ready |
| Applications | Acromegaly, neuroendocrine tumors, carcinoid syndrome, GI bleeding |
| CAS | 79517-01-4 |
|---|---|
| Applications | GEP-NETs, GI Bleeding, Postoperative Pancreatic complications |
Related products
-
Abarelix
CAS: 183552-38-7Applications: Advanced Prostate Cancer, Hormone-dependent Tumors, Testosterone Suppression -
Cagrilintide
CAS: 1415456-99-3Applications: Amylin, Diabetes adjunct therapy, obesity management, weight management -
Orforglipron
CAS: 2212020-52-3Applications: obesity management, Oral GLP-1 Development, Type 2 diabetes -
Setmelanotide
CAS: 920014-72-8Applications: Appetite Regulation, Genetic Obesity, MC4R Agonist, metabolic syndrome